Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03734029 · ClinicalTrials.gov registry record · Phase 3
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
A Phase 3 study of Breast Cancer, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 3
- Development phase
- 557
- Enrollment target
- 20
- Study locations
NCT03734029 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 557 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03734029, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 557 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: * Cannot be removed by an operation * Has spread to other parts of the body
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Eribulin
- DRUG Trastuzumab deruxtecan (DS-8201a)
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center - Deerfield Beach - Boca Raton
- Florida Cancer Specialists (South Region) - Fort Myers
- Memorial Healthcare System MRH Cancer Center - Hollywood
- Orlando Health, Inc. - Orlando
- Moffitt Cancer Center -Tampa - Tampa
California
- UCLA School of Medicine - Los Angeles
- Stanford Cancer Institute - Palo Alto
- Cancer Care Associates Medical Group, Inc. TORI - Redondo Beach
- University of California at San Francisco (PARENT) - San Francisco
Arizona
- Ironwood Cancer & Research Centers - Chandler II - Chandler
- Banner MD Anderson Cancer Center - Gilbert
- Cancer Treatment Centers of America at Western Regional Medical Center - Goodyear
Illinois
- University of Chicago Medical Center - Chicago
- Cancer Treatment Centers of America - Zion
Connecticut
- Eastern Connecticut Hematology/Oncology Assoc. - Norwich
Delaware
- Christiana Care Health Services, Inc. - Newark
Georgia
- Cancer Treatment Centers of America-Georgia - Newnan
Kansas
- Cancer Center of Kansas - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 557 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03734029
The ClinicalTrials.gov registry entry for NCT03734029 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 557 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT03734029 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03734029 about?
NCT03734029 is a clinical study titled "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]". This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: * Cannot be removed by an operation * Has spread to other parts of the body
What is the current status of trial NCT03734029?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 557 participants. The study started on 2018-12-27. Estimated completion is 2026-08-01.
What conditions does trial NCT03734029 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03734029?
The interventions under investigation include: Capecitabine (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG), Eribulin (DRUG), Trastuzumab deruxtecan (DS-8201a) (DRUG).
Who is sponsoring clinical trial NCT03734029?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03734029 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.